Payment overview · 2025
General Payments
$235,847.87
384 reported records · 34 companies
Healthcare provider profile · identity verified
Lance A Sloan, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · LUFKIN, TX · NPI 1588665228
Verified facts
What the public records show
CMS Open Payments records show Lance A Sloan, MD received $235,847.87 in general payments during 2025 across 384 reported records.
Corcept Therapeutics accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Prolia, Recorlev, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synjardy by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 626 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lantus by this doctor in 2024.
Xeris Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RECORLEV as an associated drug or biological on 10044 records involving 3629 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Recorlev by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $80,290.73 | 34.0% | 80 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71,570.26 | 30.4% | 92 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38,689.18 | 16.4% | 37 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $10,661.92 | 4.5% | 12 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $9,547.78 | 4.0% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $8,739.95 | 3.7% | 34 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $4,092.63 | 1.7% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $4,045.66 | 1.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $3,061.80 | 1.3% | 22 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $1,606.12 | 0.7% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $713.74 | 0.3% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $394.86 | 0.2% | 6 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $381.75 | 0.2% | 7 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $358.00 | 0.1% | 2 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $241.51 | 0.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.13 | 0.1% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$155.15 | 0.1% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $139.58 | 0.1% | 6 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $126.41 | 0.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $123.15 | 0.1% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $102.55 | 0.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.15 | 0.0% | 3 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $79.98 | 0.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $70.80 | 0.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $66.21 | 0.0% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $65.46 | 0.0% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $52.59 | 0.0% | 2 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $43.01 | 0.0% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $39.51 | 0.0% | 2 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $24.30 | 0.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.69 | 0.0% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $19.25 | 0.0% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $17.18 | 0.0% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $16.88 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $176,627.50 | 66 |
| Travel and Lodging | $23,384.24 | 85 |
| Consulting Fee | $12,612.00 | 8 |
| Honoraria | $11,725.00 | 4 |
| Food and Beverage | $11,464.03 | 216 |
| Education | $35.10 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $79,245.92 | 74 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $59,546.81 | 58 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45,577.78 | 59 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $10,645.79 | 9 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $9,547.78 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $8,739.95 | 34 | 2025 |
Source payment records
|
|||||
| TRYVIO Normalized: tryvio |
Drug | IDORSIA PHARMACEUTICALS US INC | $4,092.63 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $4,045.66 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $2,806.57 | 17 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $379.24 | 5 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $365.50 | 6 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $347.08 | 5 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $155.15 | 4 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $149.70 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $145.43 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $139.58 | 6 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $127.23 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $126.66 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $126.41 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $123.15 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $102.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $97.45 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $86.15 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $84.01 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $82.68 | 9 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $79.98 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $70.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $68.13 | 4 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $66.21 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $65.46 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.32 | 4 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $52.59 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.76 | 3 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| NXSTAGE SYSTEM ONE Normalized: nxstage system one |
Device | Fresenius USA Marketing, Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| NGENLA Normalized: ngenla |
Drug | PFIZER INC. | $16.13 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 212 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 224 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 86 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 395 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 626 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 27 | exact normalized | Medicare Part D |
| RECORLEV recorlev |
2025 | Recorlev | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 31 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
27 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
212 | 56 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
86 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
224 | 70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
224 | 70 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
395 | 105 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
224 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
395 | 105 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
113 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
626 | 160 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Xeris Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | RECORLEV open payments reported associated product |
CMS Open Payments — General Payments 10044 supporting records · 3629 recipient NPIs · example record 1250146588 |
Recorlev · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 626 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 140 |
| Mounjaro | Tirzepatide | 395 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 113 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 331 | 86 |
| Jardiance | Empagliflozin | 224 | 70 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 216 | 57 |
| Farxiga | Dapagliflozin Propanediol | 212 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 67 |
| Ramipril | Ramipril | 158 | 51 |
| Tresiba Flextouch U-200 | Insulin Degludec | 131 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 130 | 34 |
| Trulicity | Dulaglutide | 113 | 34 |
| Torsemide | Torsemide | 111 | 40 |
| Gabapentin | Gabapentin | 108 | 34 |
| Synthroid | Levothyroxine Sodium | 108 | 31 |
| Carvedilol | Carvedilol | 106 | 34 |
| Lisinopril | Lisinopril | 100 | 32 |
| Allopurinol | Allopurinol | 99 | 28 |
| Losartan Potassium | Losartan Potassium | 94 | 33 |
| Kerendia | Finerenone | 86 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 36 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 76 | 27 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 70 | 18 |
| Simvastatin | Simvastatin | 67 | 30 |
| Ezetimibe | Ezetimibe | 66 | 20 |
| Potassium Chloride | Potassium Chloride | 66 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 64 | 25 |
| Furosemide | Furosemide | 53 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 24 |
| Paricalcitol | Paricalcitol | 52 | 13 |
| Estradiol | Estradiol | 51 | 24 |
| Hydrocortisone | Hydrocortisone | 48 | suppressed |
| Methimazole | Methimazole | 48 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 47 | 12 |
| Metformin Hcl | Metformin Hcl | 42 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Indapamide | Indapamide | 32 | 16 |
| Insulin Lispro | Insulin Lispro | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Omeprazole | Omeprazole | 31 | suppressed |
| Spironolactone | Spironolactone | 28 | 16 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Prolia | Denosumab | 27 | 21 |
| Humalog | Insulin Lispro | 26 | 13 |
| Dexamethasone | Dexamethasone | 25 | 19 |
| Gemtesa | Vibegron | 25 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Progesterone | Progesterone, Micronized | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Xphozah | Tenapanor Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Euthyrox | Levothyroxine Sodium | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Recorlev | Levoketoconazole | 12 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 12 | suppressed |
| Cycloset | Bromocriptine Mesylate | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $235,847.87 · 384 records | Corcept Therapeutics | CeQur Simplicity, EVENITY, FARXIGA, FREESTYLE LIBRE 3, FUROSCIX, Fabhalta, Filspari, GVOKE HYPOPEN, Gazyva, IBSRELA, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, MINIMED 780G, MOUNJARO, NGENLA, NXSTAGE SYSTEM ONE, Omnipod, Ozempic, PREVNAR 20, PROLIA, Paradise Ultrasound Renal Denervation System, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, SYNTHROID, Senza, TARPEYO, TAVNEOS, TEPEZZA, TRYNGOLZA, TRYVIO, TZIELD, Wegovy, XYOSTED, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error